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1 Drug description 
Generic/Brand name:  
Trastuzumab/ Herceptin®  
Developer/Company:  
Roche  
Description:  
Trastuzumab (Herceptin®) is a humanised monoclonal antibody that binds 
to the human epidermal growth factor 2 (HER2) protein expressed on the 
cell surface, inhibiting cell proliferation. Immunohistochemistry (IHC) or 
fluorescence in situ hybridization (FISH) are typically used to assess HER2 
levels. Approximately 22 % of advanced gastric cancers overexpress HER2 
(IHC3+ and/or FISH+), a similar percentage as seen in breast cancer. A 
higher HER2-positivity rate is seen in cancer of the gastroesophageal junc-
tion than in stomach cancer. While several studies have shown HER2 over-
expression to be associated with poorer prognosis and survival, some have 
failed to find a direct association between HER2 positivity and prognosis  
[1]. 
The dosing schedule for metastatic gastric cancer is an intravenous (iv) infu-
sion with an initial loading dose of 8 mg/kg body weight, followed by 6 
mg/kg body weight every three weeks, until disease progression or unaccept-
able toxicity.  
Detection of HER2 protein overexpression is necessary for selection of pa-
tients appropriate for trastuzumab therapy. HER2 testing must be per-
formed in a specialised laboratory which can ensure adequate validation of 
the testing procedures. 
Because the use of trastuzumab is associated with cardiotoxicity, all candi-
dates for treatment with trastuzumab should undergo baseline cardiac as-
sessment including history and physical examination, electrocardiogram, 
echocardiogram, or Multi Gated Acquisition (MUGA)-scan or magnetic 
resonance imaging. Cardiac function should be further monitored during 
treatment [1]. 
2 Indication  
Trastuzumab (Herceptin®) is indicated for the treatment of patients with 
HER2 positive metastatic adenocarcinoma of the stomach or gastro-
esophageal junction in combination with capecitabine or 5-fluorouracil and 
cisplatin who have not received prior anti-cancer treatment for their metas-
tatic disease [1]. 
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3 Current regulatory status 
The European Medicines Agency (EMA) granted market authorization for 
trastuzumab (Herceptin®) in August 2000 for treatment of metastatic breast 
cancer. Current indications comprise the treatment of patients with 
  HER2 positive metastatic breast cancer as monotherapy if therapy 
with anthracycline and taxanes has failed or is contraindicated, in 
combination with paclitaxel in patients who have not received chemo-
therapy for their metastatic disease and for whom an anthracycline is 
not suitable, in combination with docetaxel in patients who have not 
received chemotherapy for their metastatic disease and in combina-
tion with an aromatase inhibitor in postmenopausal patients with 
hormone-receptor positive metastatic breast cancer, not previously 
treated with trastuzumab, 
 HER2 positive early breast cancer following surgery, chemotherapy 
(neoadjuvant or adjuvant) and radiotherapy (if applicable), 
 HER2 positive metastatic adenocarcinoma of the stomach or gastro-
esophageal junction in combination with capecitabine or 5-
fluorouracil and cisplatin who have not received prior anti-cancer 
treatment for their metastatic disease. Herceptin should only be used 
in patients with metastatic gastric cancer whose tumours have HER2 
overexpression as defined by IHC2+ and a confirmatory FISH+ re-
sult, or IHC3+, as determined by an accurate and validated assay 
(since January 2010) [1, 2]. 
 
The United States Food and Drug Administration (FDA) has granted mar-
ket authorization for trastuzumab (Herceptin®) in 1998. In the U.S., trastu-
zumab (Herceptin®) is currently approved for the treatment of early and me-
tastatic breast cancer [3]. 
4 Burden of disease 
Despite a sharp worldwide decline in incidence and mortality during the se-
cond half of the 20th century, gastric cancer remains one of the most com-
mon malignancies in the world with an estimated one million new cases and 
more than 800,000 deaths worldwide in 2007. Gastric cancer is the second 
leading cause of cancer-related death in men and fourth among women [4].  
Incidence of gastric cancer varies widely across geographic regions. The 
highest rates are found in Eastern Asia (Japan, Korea and China), Eastern 
Europe and certain countries in Central and South America. The incidence 
in women is about 50% lower than in men and generally follows a similar 
geographic pattern. Incidence of gastric cancer increases with age, with a 
peak between 50-70 years. 5-year survival rate for stomach cancer overall 
does not exceed 25% [1, 4]. 
EMA market 
authorization for HER2 
positive breast cancer 
and metastatic gastric 
cancer 
FDA approved for HER2 
positive breast cancer 
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Like worldwide, the incidence of malignant stomach tumours has decreased 
markedly in the last two decades in Austria, both in absolute numbers and 
as a percentage of new malignancies. Whereas 2,500 new cases of malignant 
tumours were reported in 1987 (8.4% of all new neoplasms), in 2007 scarcely 
1,300 neoplasms of the stomach were registered, representing a mere 3.7% of 
all new malignancies. As elsewhere, the incidence of gastric cancer in men in 
Austria is roughly two times higher than of Austrian women. Also, the mor-
tality rate has declined rapidly, from 2,045 deaths in 1987 to 934 in 2007. 
The mortality rate, per 100,000 people, has remained roughly twice as high 
for men as for women throughout this period. At the time of diagnosis, about 
1 % of diseases are carcinoma in situ, 20 % are localized, 23 % locally ad-
vanced and 17 % metastasized (unknown 26 %, death certificate only 13 
%)[5]. 
 
About 90 % of stomach tumours are adenocarcinomas, which can be subdi-
vided into two histologic subtypes (Lauren classification): well differentiated 
or intestinal type and undifferentiated or diffuse type. In addition, they may 
be classified according to their site in proximal (cardia) or distal stomach 
(non-cardia) cancers. Infection with Helicobacter pylori, atrophic gastritis, 
intestinal metaplasia and dysplasia have been identified as important steps 
in the pathogenesis of gastric cancer. A falling incidence of H. pylori infec-
tion and non‐cardia gastric cancer in developed countries is in contrast 
with increasing incidence rates of cardial and gastroesophageal junction tu-
mours. A proportion of these cases seems to be associated with Barrett's epi-
thelium (intestinal metaplasia of the distal oesophagus), developing from 
chronic oesophageal reflux disease. Although it is difficult to determine 
whether these cancers are gastroesophageal junction tumours or distal oeso-
phageal malignancies, in clinical trials for advanced disease they are usually 
treated in the same manner. There is no data on the incidence of gastroe-
sophageal junction tumours available [4, 5, 6]. 
Apart form Helicobacter pylori infection, other risk factors for gastric cancer 
are smoking, lower socioeconomic status, and dietary factors such as salty 
food as well as obesity [1].  
Stomach cancer is often asymptomatic or causes only nonspecific symptoms 
in its early stages. As it progresses, symptoms may include weight loss, ab-
dominal pain, early satiety, nausea and vomiting, bleeding and anaemia [1]. 
Tumours are staged according to the extent of invasion and spread with the 
TNM-Classification. Invasive gastric cancer (stages T2 – T4) is fatal without 
surgery. In advanced stages of gastric cancer, mean survival with best sup-
portive care is less than 6 months from diagnosis [6, 7]. 
5 Current treatment 
The aim of treatment in advanced gastric cancer is to prevent progression, 
extend survival and relieve symptoms with minimal adverse effects. 
Surgery is typically carried out in the earlier stages of gastric cancer, but 
may also be carried out in advanced stages to relieve pain and discomfort of 
the disease. In addition, chemotherapy and/or radiotherapy is offered, de-
pending on the stage of the disease and patient characteristics. The results of 
1.300 new cases of 
gastric cancer in Austria 
in 2007 
mean survival in 
advanced stages less 
than 6 months 
palliative aim of 
treatment  
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a recent meta-analysis suggest a significant and conclusive survival benefit 
for chemotherapy versus best supportive care (in this analysis, 11 versus 4.3 
months weighted average survival), as well as a modest survival benefit for 
combination versus single-agent chemotherapy. Three-drug regimens offer a 
slight advantage in overall survival compared to two-drug regimens. The 
price of the benefit is significant toxicity as a result of combination chemo-
therapy [6].  
There is no consensus about what chemotherapy agent or regimen to use. 
Commonly used regimens in gastric cancer include continuous infusion 5-
fluorouracil (5-FU) or capecitabine in combination with one or more of the 
following: cisplatin, oxaliplatin, doxorubicin, adriamycin, epirubicin, do-
cetaxel, paclitaxel and irinotecan [1, 6, 8]. 
6 Evidence 
The evidence identified for this report comprises one phase III study [1, 9] 
and two phase II studies [10, 11], all of them published only as abstracts. 
Additionally, one previous horizon scanning report on trastuzumab (Her-
ceptin®) for advanced gastric cancer was identified, which was published in 
2007 and is based on preliminary study results [12]. 
The phase III study, which compared standard chemotherapy (5-FU or cape-
citabine plus cisplatin) with and without trastuzumab, showed improved 
overall survival of patients with advanced HER2 positive gastric cancer 
treated with add-on trastuzumab. 
The toxicities in the two arms were comparable, except that a higher num-
ber of trastuzumab-treated patients had a significant decrease in left ven-
tricular ejection fraction (LVEF, ≥ 10 % from baseline to an absolute LVEF 
< 50 %: 11/237 patients, 4.6 % vs. 2/167 patients, 1.1 %). However, only one 
patient in the trastuzumab group developed grade 3 to 4 cardiac failure ver-
sus two in the control group. 
The two phase II studies described in abstracts included only a very small 
number of patients with HER2 positive tumours (n = 3 and n = 21) [10, 11]. 
In addition, published data on these studies is too sparse to take their results 
into account for evaluating the use of trastuzumab. 
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6.1 Efficacy and safety - Phase III studies 
Reference  NCT01041404, ToGA trial (BO18255) EMA assessment report, abstract published [1, 9] 
Sponsor Hoffmann-La Roche 
Country 141 study locations in 24 countries in Asia, Europe, Latin America 
Design Parallel, randomized, open label, multicentre 
Participants characteristics I1: 294 pts.2, C3: 290 pts., sex: 444 male, 140 female, median age and range in years I: 59,4 (23 – 83) C: 58,5 
(21 – 82) 
Treatments I: Trastuzumab intravenous 6 mg/kg (loading dose 8 mg/kg) every 3 weeks in addition to chemotherapy 
(see below). Treatment with trastuzumab continued until disease progression or unmanageable toxicity. 
C: Combination of 6 cycles of a fluoropyrimidine (capecitabine 1000 mg/m2 per os twice daily for 14 days 
every 3 weeks, or fluorouracil 800 mg/m2/day intravenous infusion over 5 days every 3 weeks) and cisplatin 
(80 mg/m2 as a two hour intravenous infusion every 3 weeks) 
In-/exclusion criteria Inclusion: pts. ≥ 18 years of age with inoperable locally advanced, recurrent, and/or metastatic HER2 posi-
tive adenocarcinoma of the stomach or gastroesophageal junction, ECOG PS 0, 1 or 27, LVEF ≥ 50 % 
Exclusion: pts. with previous chemotherapy for advanced/metastatic disease, lack of physical integrity of 
the upper gastrointestinal tract, or malabsorption syndrome  
Follow-up Until death or study completion (January 2009) 
Outcomes Primary: Overall survival (OS) 
Secondary:   
 Progression free survival (PFS), time to progression (TTP), overall response rate (ORR; complete 
response (CR) + partial response (PR)), clinical benefit rate (CBR; CR + PR + stable disease), du-
ration of response (DR) 
 Safety profile, quality of life (QoL), pain intensity, analgesic consumption, weight gain/loss 
 Pharmacokinetics 
Key results  
 
Primary: 
OS: HR4 0.74, 95 % CI5: 0.60 - 0.91 (median OS: I 13.8 vs. C 11.1 months, p = 0.0046) 
Secondary:   
 - PFS: HR 0.71, 95 % CI 0.59 – 0.85 (median PFS: I 6.7 vs. C 5.5 months, p = 0.0002)  
                  - TTP: HR 0.70, 95 % CI 0.58 – 0.85 (median TTP: I 7.1 vs. C 5.6 months, p = 0.0003) 
                  - ORR: Odds ratio 1.70, 95% CI 1.22 – 2.38 (Responders I 47.3 % vs. C 34.5 %, p = 0.0017) 
                  - DR: HR 0.54, 95 % CI 0.40 – 0.73 (median time to event: I 6.9 vs. C 4.8 months, p <    0.0001) 
                  - CBR: Odds ratio 1.66 95 % CI 1.14 – 2.41 (I 78.9 % vs. C 69.3 %, p = 0.0081 
 - QoL: improvements in both arms over time, gastrointestinal symptom scores slightly better in C
                  - Pain scores and analgesics use: similar in I and C 
 Pharmacokinetics: lower trastuzumab levels in gastric cancer pts. compared to metastatic breast 
cancer pts. 
Adverse effects Any adverse event (AE): I 292/294, 99% vs. C 284/290, 98 %  
Significant LVEF decreases: I 4.6 % vs. C 1.1 %, no difference in symptomatic congestive heart failure 
Grade 3/4 AE: I 201/294, 99 % vs. C 198/290, 68 % 
Treatment related deaths/deaths as a result of an adverse event: I 10/17, 59 % vs. C 3/14, 21 % 
Study withdrawals as a result of an AE: I 32 pts., 11 % vs. C 43 pts., 15 % 
Commentary The second interim efficacy analysis was performed after 349 events (patient deaths), corresponding to 
75.9 % of the planned 460 events had been reported. The IDMC6 recommended that the study be termi-
nated. 
 
1 I = Intervention 
2 pts. = Patients 
3 C = Control 
4 HR = Hazard ratio 
5 CI = Confidence interval 
6  IDMC = Independent data monitoring centre 
7ECOG = Eastern Cooperative Oncology Group Performance Status 
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The ToGA (Trastuzumab for HER2 positive metastatic gastric cancer) trial 
assessed trastuzumab in combination with a fluoropyrimidine and cisplatin 
(FP+H) versus chemotherapy alone (FP) as first line therapy in patients 
with HER2 positive advanced gastric cancer. The choice of fluoropyrimidine 
was decided by the investigator on an individual patient basis.  
Within the screening programme for the ToGA trial 3,667 evaluable patient 
samples were assessed and 810 were defined as HER2-positive (IHC3+ 
and/or FISH+; HER2-positivity rate of 22.1%). 
Patients previously untreated for HER2 positive inoperable locally advanced 
or recurrent and/or metastatic adenocarcinoma of the stomach or gastro-
oesophageal junction not amenable to curative therapy (some have had ad-
juvant chemotherapy for gastric cancer before) were included. They were 
stratified prior to randomization for a number of parameters, including 
prognostic factors that could affect outcome: Eastern Cooperative Oncology 
Group (ECOG) performance status (0-1 vs. 2), chemotherapy regimen (5-FU 
plus cisplatin vs. capecitabine plus cisplatin), locally advanced vs. metastatic 
disease, stomach vs. gastro-esophageal junction, and measurable vs. non-
measurable evaluable disease.  
Following the HER2 testing, patients were classified in different HER2 sub-
groups. Overall, the proportion of patients with low HER2 overexpression 
(IHC0/FISH+, IHC1+/FISH+) was small (22 %) as compared to patients 
with high HER2 (IHC2+/FISH+, IHC3+) overexpression (76 %).  
During the course of the trial, the independent data monitoring centre 
(IDMC) advised the sample size to be increased from 248 events to 460 
events. In addition, following the 1st interim analysis after 50 % of the 460 
events, IDMC recommended an additional interim analysis, which was per-
formed when 349 (75.9 %) of the events had been reported in the study 
across the two treatment arms. The results were reviewed by the IDMC, who 
recommended that the study should be terminated.  
Treatment with trastuzumab in combination with FP chemotherapy re-
sulted in a significant improvement in overall survival compared to treat-
ment with FP alone at approximately 1.5 years of follow up (median of fol-
low up 17.1 months in the FP arm and 18.6 months in the FP+H). At this 
point, there were 182 deaths in the FP arm and 167 deaths in the FP+H arm 
(62.8 % vs. 56.8 %), an absolute risk reduction of 6 % (Number needed to 
treat (NNT) 17). The majority of the deaths were due to events related to the 
underlying cancer. In addition to fewer deaths, the median overall survival 
time in the FP+H arm was extended to 13.8 months compared to 11.1 
months in the FP arm. This corresponds to a statistically significant reduc-
tion in the risk of death by 26% for patients treated with trastuzumab plus 
FP (hazard ratio (HR) 0.74; 95% CI 0.60-0.91, p = 0.0046). 
Consistent effects were observed in the secondary endpoints. Significant 
benefit from the addition of trastuzumab to FP therapy was seen for pro-
gression-free survival, overall response rate, time to progression, duration of 
response and clinical benefit rate (see table for details). 
Post-hoc subgroup analyses indicated that positive treatment effects are lim-
ited to targeting tumours with higher levels of HER2 protein. The median 
overall survival for the high HER2 expressing group (IHC2+/FISH+, 
IHC3+) was 16 months versus 11.8 months for the low HER2 expressing 
group (HR 0.65; 95 % CI 0.51-0.83). In contrast, in patients with low HER2-
expressing tumours (IHC0/FISH+ and IHC1+/FISH+), limited treatment 
trastuzumab in addition 
to standard 
chemotherapy was 
compared to standard 
chemotherapy alone  
the trial was stopped 
early for benefit  
median overall survival 
was extended by 2.7 
months in the 
trastuzumab group 
benefit might be limited 
to targeting tumours 
with high levels of HER2 
protein expression  
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benefit was observed (median survival times of 8.7 and 10 months in the FP 
and FP+H arms, respectively, HR 1.07; 95% CI 0.70-1.62). 
Subgroup analyses as well created doubt regarding the benefit of add-on 
trastuzumab treatment in other patient subgroups, for instance those with 
locally advanced disease, non-measurable disease and poor performance 
status (ECOG 2). Therefore, these patients were excluded from the indica-
tion.  
The most common adverse events in both treatment arms were nausea, vom-
iting, neutropenia and anorexia. Apart from the above mentioned decrease 
of LVEF, adverse events which occurred with a higher frequency in the 
FP+H arm than in the FP arm (≥ 5% difference) included diarrhea, stoma-
titis, anemia and thrombocytopenia.  
The frequency of infections was higher in patients treated with fluoro-
pyrimidine, cisplatin and trastuzumab, compared with those treated with 
fluoropyrimidine and cisplatin (32% versus 20%) and two patients in the 
trastuzumab containing arm died because of pneumonia, versus none in the 
fluoropyrimidine and cisplatin arm.  
Overall, the incidence of Grade ≥ 3 adverse events was similar in the two 
treatment groups (68% in each arm). Neutropenia, commonly associated 
with fluoropyrimidine plus platinum therapy, was the most common Grade 
≥ 3 event in both treatment arms (29% in FP, 35% in FP+H). An increased 
incidence of Grade 3 or 4 diarrhea was reported in the FP + H arm (9 % vs. 
4 %). Seventeen patients (6%) experienced at least one typical infusion-
related AE of CTC Grade ≥ 3 on the day of or the day after a trastuzumab 
infusion.  
Taken together, safety data from the ToGA trial suggest that there are no 
additional significant safety issues with trastuzumab used in the treatment 
of advanced gastric cancer over and above those seen when it is used to treat 
breast cancer. Therefore, risks of cardiac dysfunction and pulmonary, gas-
trointestinal and infusion-related adverse reactions persist [1]. 
6.2 Efficacy and safety - further studies 
Two phase II trials were available only as abstracts [10, 11]. One describes a 
partial response to trastuzumab monotherapy sustained for > 24 weeks for 
one out of three treated patients [11], whereas the other reported response in 
six out of 21 treated patients treated with trastuzumab in combination with 
cisplatin [10]. 
trastuzumab was 
associated with decrease 
in LVEF and 
gastrointestinal toxicity 
no other phase II/III 
trials published in full 
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7 Estimated costs 
One vial Herceptin® containing 150 mg costs € 715 [13]. Hence, a loading 
dose of trastuzumab 8 mg/kg costs approximately € 2,860.-, and € 2,145.- for 
each subsequent 6 mg/kg dose1 [13]. The median treatment duration in pa-
tients treated with trastuzumab in the ToGA study was 4.9 months (equating 
to approximately 6 x 3 week cycles). Trastuzumab over this time period 
would cost approximately € 13,585.- per patient. This is in addition to cur-
rent chemotherapy costs. Other costs include the preliminary assessment of 
HER2 levels in all patients (on average, approximately 6 patients have to be 
screened to find one with high overexpression of HER2), regular measure-
ment of LVEF by echocardiogram before and during treatment (approxi-
mately every three months) and treatment of patients developing trastuzu-
mab-related cardiotoxicity. 
High HER2 expressing tumours (IHC2+/FISH+ or IHC3+) were found in 
16 % of patients of the ToGA study. About 17 % of the 1300 newly diagnosed 
gastric cancers in Austria are metastasized [5]. According to its indication 
for metastasized gastric cancer, trastuzumab might be offered to an esti-
mated 35 patients per year. Thus, the costs for the drug itself will raise the 
treatment costs for gastric cancer by approximately € 475,000 per year. 
8 Ongoing research 
There are no other ongoing or completed phase II/III trials for trastuzumab 
in advanced gastric cancer registered [14].  
However, trastuzumab is tested in a variety of other HER2 positive neo-
plasms such as breast cancer, pancreatic cancer, endometrial cancer, bladder 
cancer, lung cancer, prostate cancer, sarcoma and B-acute lymphoblastic 
leukemia, in most of these neoplasms in combination with other cytotoxic 
drugs. 
In advanced gastric cancer, other monoclonal antibodies such as cetuximab, 
bevacizumab and panitumumab are currently investigated in phase III clini-
cal trials [14]. 
                                                             
1 calculated for a 70 kg person and per package 
loading dose ca. € 
2,860.- subsequent 
doses ca. € 2,145.- until 
disease progression 
no other phase II/III 
trials for advanced 
gastric cancer registered 
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9 Commentary 
The EMA extended the indication for the use of trastuzumab for the treat-
ment of patients who were previously untreated for HER2 positive metas-
tatic adenocarcinoma of the stomach or gastroesophageal junction in combi-
nation with capecitabine or 5-FU and cisplatin in January 2010 based on the 
results of one randomised, open-label phase III study which demonstrated 
increased overall survival [1]. At a median follow up of approximately 1.5 
years, treatment with trastuzumab in combination with FP chemotherapy 
resulted in a significant improvement in overall survival compared to treat-
ment with FP alone (median overall survival 11.1 vs. 13.8 months, HR 0.74, 
95% CI 0.60-0.91, p = 0.0046) [1]. 
The toxicity of both treatment arms in the ToGA trial was comparable. How-
ever, treatment duration with trastuzumab was short and a longer exposition 
might lead to a higher cardiotoxicity [15]. 
Quality of life was assessed using standardized quality of life questionnaires 
for cancer patients (EORTC QLQ-C30, gastric module STO22). The actual 
scores and change from baseline indicated improved quality of life in both 
treatment arms over time, especially at the end of chemotherapy, but no 
added value for trastuzumab. On the contrary, gastrointestinal symptom 
scores were slightly worse in patients receiving trastuzumab which correlates 
with the slightly increased frequency of gastrointestinal adverse events in 
these patients. Pains scores and use of analgesics were similar in both arms 
[1].  
However, the favourable efficacy results of the study should be interpreted 
with some caution, since it has been shown that efficacy results of random-
ized controlled trials (RCTs) stopped early for benefit are prone to exaggera-
tion. The observed treatment effect may therefore be a chance finding [16, 
17].  
The indication of trastuzumab for patient subgroups in advanced gastric 
cancer was based on the results of post-hoc subgroup analyses which sug-
gested that positive treatment effects are limited to targeting tumours with 
higher levels of HER2 protein, whereas no apparent benefit was seen in pa-
tients with poor performance status at baseline, non-measurable and locally 
advanced disease. Accordingly, these patients were excluded from the indi-
cation. Analysed subgroups were small (e. g., locally advanced disease n = 
20 patients). Post-hoc subgroup observations, in general, should be treated 
with scepticism [18]. Hence, these results need to be confirmed in further 
trials. 
In addition, patients with a lack of physical integrity of the upper gastroin-
testinal tract or malabsorption syndrome, and patients with acute intestinal 
bleeding were not allowed to enter the study. Therefore the target patient 
population may not be representative for those patients which will be 
treated with trastuzumab after market authorization [1].  
Since the optimal duration of trastuzumab therapy is not known further tri-
als assessing metastasized gastric cancer should investigate when treatment 
with trastuzumab can be stopped and whether patients can benefit from a 
prolonged administration of chemotherapeutic agents. In addition, the role 
of newer agents such as taxanes for the treatment of advanced gastric cancer 
has to be defined. 
EMA granted market 
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gastroesophageal 
junction in combination 
with a fluorouracil and 
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trastuzumab 
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Analysis of pharmacokinetics of trastuzumab in gastric cancer gave 
remarkable differences to pharmacokinetics in breast cancer, e.g., lower 
trough concentrations. Further clarification on the involved mechanisms is 
needed. 
It is likely that trastuzumab will be used more frequently in the near future. 
Off label use will probably be practised in patient subgroups currently ex-
cluded from the indication, such as locally advanced disease. Also, other 
HER2 positive neoplasms might be treated with trastuzumab. 
Despite the limitations of the available data, tumours of patients with me-
tastasized gastric cancer who are potential candidates for 
trastuzumab should be screened for overexpression of HER2. It is reason-
able to offer trastuzumab in addition to standard chemotherapy if the tu-
mour expresses high levels of HER2 protein (IHC2+/FISH+ and 
IHC3+/regardless of the FISH status), after explaining to the patient the 
possible risks and benefit of the treatment. 
The use of trastuzumab will raise the costs for the treatment of gastric can-
cer. The expensive drug is to be continued until the disease progresses and 
will most likely be used off-label. Furthermore, there are indirect costs such 
as screening tumours for HER2 overexpression and cardiac monitoring of 
patients. 
 
use of trastuzumab will 
probably increase 
trastuzumab should be 
offered to patients with 
HER2 positive 
metastatic gastric 
cancer 
trastuzumab will raise 
the treatment costs for 
gastric cancer  
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